A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Otsuka Call Center
- 電話番号:844-687-8522
- メール:otsuka-professionalservices@otsuka-us.com
研究場所
-
-
Florida
-
Gainesville、Florida、アメリカ、32607
- 募集
- Sarkis Clinical Trials - Gainesville
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Sarkis
-
Jacksonville、Florida、アメリカ、32256
- 募集
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
主任研究者:
- Jones
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland、Florida、アメリカ、32751
- 募集
- Accel Research Sites-Maitland
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Marraffino
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70125
- 募集
- Nola Research Works
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Hebert
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02132
- 募集
- Boston Clinical Trials
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Mezhebovsky
-
Watertown、Massachusetts、アメリカ、02472
- 募集
- Adams Clinical - Watertown
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Rutrick
-
-
Missouri
-
Saint Charles、Missouri、アメリカ、63304
- 募集
- St. Charles Psychiatric Associates/Midwest Research Group
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Mattingly
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89128
- 募集
- Center for Psychiatry and Behavioral Medicine. Inc.
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Childress
-
-
New Jersey
-
Cherry Hill、New Jersey、アメリカ、08002
- 募集
- Center for Emotional Fitness
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Corcoran
-
-
New York
-
New York、New York、アメリカ、10128
- 募集
- The Medical Research Network, LLC
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Careri
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45215
- 募集
- Patient Priority Clinical Trials
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Popovitz
-
-
Oregon
-
Portland、Oregon、アメリカ、97210
- 募集
- Summit Research Network
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Essink
-
-
Texas
-
Austin、Texas、アメリカ、78737
- 募集
- Donald J. Garcia, Jr, MD, PA
-
主任研究者:
- Garcia
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire、Texas、アメリカ、77401
- 募集
- Houston Clinical Trials LLC
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Katic
-
Houston、Texas、アメリカ、77089
- 募集
- Kaleidoscope Clinical Research
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Higgins
-
-
Washington
-
Everett、Washington、アメリカ、98201
- 募集
- Core Clinical Research
-
コンタクト:
- Otsuka Call Center
- 電話番号:844-687-8522
- メール:Otsuka-ProfessionalServices@otsuka-us.com
-
主任研究者:
- Knutson
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
時間枠:Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
時間枠:Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Up to Week 9
|
Up to Week 9
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 405-201-00231
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD 共有時間枠
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD 共有アクセス基準
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。